Skip to main content
Grafa
Palvella Therapeutics granted FDA rolling review for QTORIN
Image for illustrative purposes only. Not a real photo.

Palvella Therapeutics granted FDA rolling review for QTORIN

Share

Palvella Therapeutics (NASDAQ:PVLA) announced that the FDA granted rolling review for its rare genetic disease drug application.

More ways to discover

Browse United States newsDiscover NYSE signalsBrowse all NYSE stocksBrowse all NYSE ETFsExplore United States companiesFind the right NYSE index